Merus inches up after IPO

Bispecific antibody developer Merus B.V. (NASDAQ:MRUS) rose $0.04 to $10.04 in its first

Read the full 135 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE